ClinicalTrials.gg

Program

SP-102

A development code.

Its studies are mostly in Sciatica, led by 2 companies.

Furthest: phase 3, since May 6, 20263 company-led studies, 1 open or runningNext primary completion: Nov 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Semnur Pharmaceuticals21 open or runningphase 3since May 6, 2026Jul 9, 2018Nov 2028phase 3 · NCT07579351
Scilex Pharmaceuticals10 open or runningphase 3since Dec 8, 2017Dec 8, 2017none ahead

Also a collaborator on its studies: syngene and cromos-pharma-llc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 8, 2017First study: phase 3 study in SciaticaNew to Scilex PharmaceuticalsScilex Pharmaceuticals · NCT03372161 · 401 enrolled · United States
  2. Jul 9, 2018Semnur Pharmaceuticals's first study: phase 2 study in SciaticaNew to Semnur PharmaceuticalsSemnur Pharmaceuticals · NCT03613662 · 19 enrolled · United States
  3. May 6, 2026Phase 3 study in SciaticaPhase 3 reachedSemnur Pharmaceuticals · NCT07579351 · 755 planned

Ahead

  1. Nov 2028Primary completion: phase 3 study in SciaticaSemnur Pharmaceuticals · NCT07579351

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07579351Sciatica3Not yet recruitingSemnur PharmaceuticalsNov 2028755
NCT03613662Sciatica · United States2CompletedSemnur PharmaceuticalsMar 15, 201919
NCT03372161Sciatica · United States3CompletedScilex PharmaceuticalsAug 20, 2021401

How it is read

Names in the registry

  • “SP-102”, 3 entries

Codes read as this program: SP102.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.